MAPT and cancer: Despite our lead compounds being described as dual mTORC1/2 inhibitors from studies in vitro and in cancer cells, we found that tau clearance in neurons was mainly achieved through mTORC1 inhibition (Fig. 6b–i), with less than a 10% effect on P-AKTS473 levels (Supplementary Fig. 7b, c).